Key Highlights: Implications: ChrysCapital’s planned 20–25% stake in Linux Laboratories values the CNS‑focused branded‑generics company at roughly ₹2,400–3,000 crore, reflecting investor confidence in chronic‑therapy portfolios with strong brands in neurology, psychiatry and cosmetic dermatology. The deal gives ChrysCapital another domestic formulations platform to pair with its existing healthcare investments (including Novartis India, Eris, Mankind and La Renon), while enabling Linux to...
Relevant Market Insights India’s biopharmaceutical sector is at a pivotal point in its evolution. Long celebrated as the world’s “pharmacy of the world” for generics and vaccines, the broader biopharma market is now defined by robust growth, expanding innovation, and compelling projections for the coming decade. Supported by strong domestic demand, favourable government policy, and...
Latest Developments in Specialty Pharma India’s pharmaceutical industry has built a global reputation as a leading supplier of affordable generic medicines. Over the past two decades, Indian companies have established strong capabilities in large-scale manufacturing, regulatory compliance, and cost-efficient drug production. However, as global competition intensifies and pricing pressures increase in traditional generics markets, many...
Summary The Top 10 R&D Spending Indian Biopharma Companies of 2026 reflect the country’s growing commitment to pharmaceutical innovation, advanced drug development, and long-term global competitiveness. Led by Sun Pharmaceutical Industries, Dr. Reddy’s Laboratories, and Zydus Lifesciences, these companies collectively invested billions of rupees in research and development during FY2025-26 to strengthen pipelines across specialty medicines, biosimilars, biologics, vaccines, complex...
Summary: The Top 10 Indian Pharmaceutical Companies of 2026 demonstrate the continued strength and global competitiveness of India’s pharmaceutical sector, led by Sun Pharmaceutical Industries, Dr. Reddy’s Laboratories, and Cipla. Collectively, these companies reported strong revenue performance driven by growth in specialty medicines, biosimilars, vaccines, chronic therapies, respiratory care, and global generics. While most companies...
Key Highlights: Implications: ChrysCapital’s planned 20–25% stake in Linux Laboratories values the CNS‑focused branded‑generics company at roughly ₹2,400–3,000 crore, reflecting investor confidence in chronic‑therapy portfolios with strong brands in neurology, psychiatry and cosmetic dermatology. The deal gives ChrysCapital another domestic formulations platform to pair with its existing healthcare investments (including Novartis India, Eris, Mankind and La Renon), while enabling Linux to...
Key Highlights: Implications: Dr. Reddy’s has secured CDSCO approval for its abatacept biosimilar (250 mg IV) for adults with moderate‑to‑severe active rheumatoid arthritis and active psoriatic arthritis who failed other DMARDs, with manufacturing at its Bachupally biologics facility and supply support from Gland Pharma. The approval is conditional on a Phase IV study (protocol due within 3...
